Product Overview
Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase (Omicron variant, BA.1.1) encodes the antigenomic-sense (or positive-sense) RNA of a replicaton-restricted recombinant vesicular stomatitis virus (rVSV) in which the glycoprotein (G) gene has been replaced with SARS-CoV-2 spike protein (A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F). Because the infectivity of Pseudotyped VSV-SARS-CoV-2 S-ΔG-Luciferase is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. The pseudotype VSV particles encode Luciferase together with the VSV nucleocapsid (N), phosphoprotein (P), glycoprotein (G), and large polymerase subunit (L) in their pVSV-ΔG vector. When the VSV pseudovirus infect the target cells, Luciferase expression is proportional to the number of cells that were infected.
COA
Publication 
Loading ......
